Hormonelle Kontrazeption und Krebs

Die International Agency for Research on Cancer (IARC) erachtet kombinierte orale Kontrazeptiva für Menschen als karzinogen, da sie das Risiko für Mamma-, Zervix- und Leberzellkarzinome erhöhen. Gleichzeitig betont die IARC jedoch, dass orale Kontrazeptiva gegen einige Arten von Karzinomen (Endometrium-, Ovarialkarzinom) protektiv wirken [1]. Dieser Beitrag beleuchtet die Problematik anhand der aktuellen Literatur.

Schlüsselwörter

Orale Kontrazeptiva - Krebsrisiko - COC - POC - Risikoerhöhung - protektiver Effekt

• Literatur

• 1 International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 91. Combined estrogen-progestogen contraceptives and combined estrogen-progesteron menopausal therapy are carcinogenic to humans. Lyon, Frankreich: IARC; 2007
• 2 Siersbaek R, Kumar S, Carroll JS. Signaling pathways and steroid receptors modulating estrogen receptor alpha function in breast cancer. Genes Dev 2018; 32: 1141-1154 doi:10.1101/gad.316646.118
• 3 Emons G. Sexualsteroide und ihre onkogene Potenz. Gynäkologische Endokrinologie 2010; 8: 7-12 doi:10.1007/s10304-009-0333-6
• 4 Sigl V, Jones LP, Penninger JM. RANKL/RANK: from bone loss to the prevention of breast cancer. Open Biol 2016; 6: pii:160230 doi:10.1098/rsob.160230
• 5 Charlton BM, Rich-Edwards JW, Colditz GA. et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nursesʼ Health Study: prospective cohort study. BMJ 2014; 349: g6356 doi:10.1136/bmj.g6356
• 6 Soini T, Hurskainen R, Grenman S. et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014; 124: 292-299 doi:10.1097/AOG.0000000000000356
• 7 Morch LS, Skovlund CW, Hannaford PC. et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 2017; 377: 2228-2239 doi:10.1056/NEJMoa1700732
• 8 Busund M, Bugge NS, Braaten T. et al. Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study. Int J Cancer 2018; 142: 2293-2302 doi:10.1002/ijc.31266
• 9 Emons G. Hormonelle Kontrazeption und Krebs. Gynäkologe 2015; 48: 651-656 doi:10.1007/s00129-015-3745-5
• 10 Iversen L, Fielding S, Lidegaard O. et al. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. BMJ 2018; 362: k3609 doi:10.1136/bmj.k3609
• 11 Butt SA, Lidegaardi O, Skovlund C. et al. Hormonal contraceptive use and risk of pancreatic cancer-A cohort study among premenopausal women. PLoS One 2018; 13: e0206358 doi:10.1371/journal.pone.0206358
• 12 Hargreave M, Morch LS, Andersen KK. et al. Maternal use of hormonal contraception and risk of childhood leukaemia: a nationwide, population-based cohort study. Lancet Oncol 2018; 19: 1307-1314 doi:10.1016/S1470-2045(18)30479-0
• 13 Iversen L, Sivasubramaniam S, Lee AJ. et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitionersʼ Oral Contraception Study. Am J Obstet Gynecol 2017; 216: 580.e1-580.e9 doi:10.1016/j.ajog.2017.02.002
• 14 Vessey M, Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception 2013; 88: 678-683 doi:10.1016/j.contraception.2013.08.008
• 15 Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727 doi:10.1016/s0140-6736(96)90806-5
• 16 Gierisch JM, Coeytaux RR, Urrutia RP. et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013; 22: 1931-1943 doi:10.1158/1055-9965.EPI-13-0298
• 17 Beaber EF, Buist DS, Barlow WE. et al. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res 2014; 74: 4078-4089 doi:10.1158/0008-5472.CAN-13-3400
• 18 Marchbanks PA, Curtis KM, Mandel MG. et al. Oral contraceptive formulation and risk of breast cancer. Contraception 2012; 85: 342-350 doi:10.1016/j.contraception.2011.08.007
• 19 Beaber EF, Malone KE, Tang MT. et al. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev 2014; 23: 755-764 doi:10.1158/1055-9965.EPI-13-0944
• 20 Group ECW. Hormones and breast cancer. Hum Reprod Update 2004; 10: 281-293 doi:10.1093/humupd/dmh025
• 21 Samson M, Porter N, Orekoya O. et al. Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat 2016; 155: 3-12 doi:10.1007/s10549-015-3663-1
• 22 Backman T, Rauramo I, Jaakkola K. et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005; 106: 813-817 doi:10.1097/01.AOG.0000178754.88912.b9
• 23 Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011; 83: 211-217 doi:10.1016/j.contraception.2010.11.009
• 24 Del Pup L, Codacci-Pisanelli G, Peccatori F. Breast cancer risk of hormonal contraception: Counselling considering new evidence. Crit Rev Oncol Hematol 2019; 137: 123-130 doi:10.1016/j.critrevonc.2019.03.001
• 25 Cibula D, Gompel A, Mueck AO. et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010; 16: 631-650 doi:10.1093/humupd/dmq022
• 26 La Vecchia C, Boccia S. Oral contraceptives, human papillomavirus and cervical cancer. Eur J Cancer Prev 2014; 23: 110-112 doi:10.1097/CEJ.0000000000000000
• 27 Walker JL, Powell CB, Chen LM. et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 2015; 121: 2108-2120 doi:10.1002/cncr.29321
• 28 Collaborative Group on Epidemiological Studies of Ovarian Cancer. Beral V, Doll R. et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303-314 doi:10.1016/S0140-6736(08)60167-1
• 29 Faber MT, Jensen A, Frederiksen K. et al. Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer. Cancer Causes Control 2013; 24: 2197-2206 doi:10.1007/s10552-013-0296-8
• 30 La Vecchia C, Bosetti C. Oral contraceptives and neoplasms other than breast and female genital tract. Eur J Cancer Prev 2009; 18: 407-411 doi:10.1097/CEJ.0b013e32832caaca
• 31 Havrilesky LJ, Gierisch JM, Moorman PG. et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep) 2013; 1-514
• 32 McGlynn KA, Sahasrabuddhe VV, Campbell PT. et al. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer 2015; 112: 1266-1272 doi:10.1038/bjc.2015.58
• 33 Tang B, Lv J, Li Y. et al. Relationship between female hormonal and menstrual factors and pancreatic cancer: a meta-analysis of observational studies. Medicine (Baltimore) 2015; 94: e177 doi:10.1097/MD.0000000000000177
• 34 Liu H, Wang XC, Hu GH. et al. Oral contraceptive use and kidney cancer risk among women: evidence from a meta-analysis. Int J Clin Exp Med 2014; 7: 3954-3963
• 35 Zamora-Ros R, Rinaldi S, Biessy C. et al. Reproductive and menstrual factors and risk of differentiated thyroid carcinoma: the EPIC study. Int J Cancer 2015; 136: 1218-1227 doi:10.1002/ijc.29067
• 36 Wu W, Yin ZH, Guan P. et al. Association of oral contraceptives use and lung cancer risk among women: an updated meta-analysis based on cohort and case-control studies. Asian Pac J Cancer Prev 2014; 15: 1205-1210 doi:10.7314/apjcp.2014.15.3.1205
• 37 Moorman PG, Havrilesky LJ, Gierisch JM. et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 2013; 31: 4188-4198 doi:10.1200/JCO.2013.48.9021
• 38 Huber D, Seitz S, Kast K. et al. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer – a systematic review. 2020 [in press]
• 39 Kotsopoulos J, Lubinski J, Moller P. et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat 2014; 143: 579-586 doi:10.1007/s10549-013-2823-4
• 40 Hormonal Contraception. Guideline of the German Society of Gynecology and Obstetrics (S3-Level, AWMF Registry No. 015/015, December 2018). Im Internet: http://www.awmf.org/leitlinien/detail/II/015-015.html Stand: 19.12.2019
• 41 Dashti SG, Chau R, Ouakrim DA. et al. Female hormonal factors and the risk of endometrial cancer in Lynch syndrome. JAMA 2015; 314: 61-71 doi:10.1001/jama.2015.6789
• 42 Gompel A, Ramirez I, Bitzer J. et al. Contraception in cancer survivors – an expert review Part I. Breast and gynaecological cancers. Eur J Contracept Reprod Health Care 2019; 24: 167-174 doi:10.1080/13625187.2019.1602721
• 43 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom, Langversion 1.0, 2018, AWMF-Registernummer 032/034-OL. Im Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/ Stand: 09.12.2019
• 44 Cagnacci A, Ramirez I, Bitzer J. et al. Contraception in cancer survivors – an expert review Part II. Skin, gastrointestinal, haematological and endocrine cancers. Eur J Contracept Reprod Health Care 2019; 24: 299-304 doi:10.1080/13625187.2019.1604947
• 45 Committee opinion no. 606: Options for prevention and management of heavy menstrual bleeding in adolescent patients undergoing cancer treatment. Obstet Gynecol 2014; 124: 397-402 doi:10.1097/01.AOG.0000452745.44206.c3
• 46 Quinn MM, Letourneau JM, Rosen MP. Contraception after cancer treatment: describing methods, counseling, and unintended pregnancy risk. Contraception 2014; 89: 466-471 doi:10.1016/j.contraception.2014.01.014
• 47 Zhong GC, Cheng JH, Xu XL. et al. Meta-analysis of oral contraceptive use and risks of all-cause and cause-specific death. Int J Gynaecol Obstet 2015; 131: 228-233 doi:10.1016/j.ijgo.2015.05.026